Symbicort is a brand name of budesonide/formoterol, approved by the FDA in the following formulation(s):
SYMBICORT (budesonide; formoterol fumarate dihydrate - aerosol, metered; inhalation)
Manufacturer: ASTRAZENECA
Approval date: July 21, 2006
Strength(s): 0.08MG/INH;0.0045MG/INH [RLD], 0.16MG/INH;0.0045MG/INH [RLD]
Has a generic version of Symbicort been approved?
No. There is currently no therapeutically equivalent version of Symbicort available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Symbicort. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Aerosol dispenser comprising an indicator assembly
Patent 5,349,945
Issued: September 27, 1994
Inventor(s): Wass; Anthony C. L. & Law; Brian R.
Assignee(s): Minnesota Mining and Manufacturing Company
An aerosol dispenser for use with an aerosol vial. The dispenser contains an assembly that indicates the quantity of doses dispensed from or remaining in the aerosol vial. The assembly comprises a rotatable indicator comprising a circumferential rack that is engaged by a worm-gear. Reciprocal movement of an aerosol vial within the dispenser causes rotation of the worm-gear which in turn causes rotation of the rack.Patent expiration dates:
- November 12, 2011✓
- November 12, 2011
Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders
Patent 5,674,860
Issued: October 7, 1997
Inventor(s): Carling; Christer Carl Gustav & Trofast; Jan William
Assignee(s): Astra Aktiebolag
Effective amounts of formoterol and/or a physiologically acceptable salt and/or solvate thereof and budesonide are used in combination for simultaneous, sequential or separate administration by inhalation in the treatment of an inflammatory respiratory disorder, such as asthma.Patent expiration dates:
- October 7, 2014✓✓
- October 7, 2014
Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof
Patent 5,972,919
Issued: October 26, 1999
Inventor(s): Carling; Christer Carl Gustav & Trofast; Jan William
Assignee(s): Astra Aktiebolag
Effective amounts of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide are used in combination for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorder.Patent expiration dates:
- December 17, 2012✓✓
- December 17, 2012
Pressurized aerosol inhalation compositions
Patent 6,123,924
Issued: September 26, 2000
Inventor(s): Mistry; Suresh N & Gibson; Mark
Assignee(s): Fisons plc
Pressurized aerosol inhalation composition consisting essentially of a liquefied hydrofluoroalkane, a powdered medicament dispersible to form a suspension in the liquefied hydrofluoroalkane, and polyvinylpyrrolidone present in a concentration of 0.00001 to 10% w/w.Patent expiration dates:
- September 26, 2017✓
- September 26, 2017
Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane
Patent 6,641,800
Issued: November 4, 2003
Inventor(s): Suresh N; Mistry & Mark; Gibson
Assignee(s): Fisons Ltd.
Pressurized aerosol composition for administration by inhalation comprising a liquefied hydrofluoroalkane, a powdered medicament dispersed therein, and a suspending agent comprising a polymer soluble in the liquefied hydrofluoroalkane which is selected from polymers including recurring amide containing structural units, copolymers of amide containing units and carboxylic acid ester units, polyvinylacetate and acrylic acid/methacrylic acid ester copolymers.Patent expiration dates:
- September 23, 2012✓
- September 23, 2012
Inhalation device
Patent 7,367,333
Issued: May 6, 2008
Inventor(s): Hodson; Darren & Rasmussen; Jorgen
Assignee(s): AstraZeneċa AB
Actuator for an inhaler for delivering medicament by inhalation. The actuator includes a main body having a tubular member for receiving a canister containing medicament and having a valve stem extending therefrom, and an outlet assembly, as a part formed separately of the main body, having a mouthpiece for guiding medicament to the mouth of a user and a nozzle block for receiving the valve stem of the canister and delivering medicament from the canister into the mouthpiece. At least a part of the outlet assembly is configured so as to deform and optionally break on withdrawal of the outlet assembly from the main body so as to prevent re-use of the outlet assembly.Patent expiration dates:
- November 11, 2018✓
- November 11, 2018
Inhaler device counter
Patent 7,587,988
Issued: September 15, 2009
Inventor(s): Bowman; Nic & Bradshaw; Douglas & Sörby; Lennart
Assignee(s): AstraZeneca AB
Inhaler counter (20) comprising a counter housing (390), a rocker arm (200) with a pawl (210), the rocker arm being pivotally supported by the housing and arranged to perform a rocker movement in response to a linear actuation motion, a return spring (220) for resetting the rocker arm, a ratchet wheel (230) engagable with the pawl to convert the movement of the rocker arm into an incremental rotational motion of an axle arrangement (240) advancing a display means (60), the axle arrangement further comprising a back rotation prevention means (280) in the form of a spring loaded friction brake and a worm gear, the display means comprising rotatable indicator means (120) with teeth that engage the worm-gear and a stationary scale.Patent expiration dates:
- April 10, 2026✓
- April 10, 2026
Composition for inhalation
Patent 7,759,328
Issued: July 20, 2010
Inventor(s): Govind; Nayna & Marlow; Maria
Assignee(s): AstraZeneca AB
The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.Patent expiration dates:
- January 29, 2023✓✓
- January 29, 2023
Use for budesonide and formoterol
Patent 7,897,646
Issued: March 1, 2011
Inventor(s): Bauer; Carl-Axel & Trofast; Jan
Assignee(s): AstraZeneca AB
The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.Patent expiration dates:
- September 9, 2018✓
- September 9, 2018
Inhalation device
Patent 7,967,011
Issued: June 28, 2011
Inventor(s): Hodson; Darren & Rasmussen; Jorgen
Assignee(s): AstraZeneca AB
Actuator for an inhaler for delivering medicament by inhalation, having a mouthpiece for guiding medicament to the mouth of a user; and a removable protection cap for the mouthpiece. The cap is secured to the mouthpiece by a cap retaining member that engages a mating recess in the mouthpiece outer periphery. The cap includes at least one release button arranged to provide an elastic deformation of the cap inner periphery that disengages the cap retaining member from the recess.Patent expiration dates:
- August 11, 2021✓
- August 11, 2021
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- February 27, 2012 - TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
See also...
- Symbicort Consumer Information (Drugs.com)
- Symbicort Aerosol Consumer Information (Wolters Kluwer)
- Symbicort Consumer Information (Cerner Multum)
- Symbicort Advanced Consumer Information (Micromedex)
- Symbicort 100 Turbuhaler Advanced Consumer Information (Micromedex)
- Symbicort 200 Turbuhaler Advanced Consumer Information (Micromedex)
- Budesonide/Formoterol Aerosol Consumer Information (Wolters Kluwer)
- Budesonide and formoterol inhalation Consumer Information (Cerner Multum)
- Budesonide and formoterol Inhalation Advanced Consumer Information (Micromedex)
No comments:
Post a Comment